Namodenoson NEW
| Price | $31 | $72 | $122 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Namodenoson | CAS No.: 163042-96-4 |
| Purity: 99.4% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Namodenoson |
| Description | Namodenoson (2-Cl-IB-MECA) is an adenosine A3 receptor agonist. |
| Animal Research | Rats were randomly assigned to two treatment groups of 6 animals, which received either two subsequent intravenous infusions of 200 μg/kg 2-chloro-N^6-(3-iodobenzyl)adenosine-5′-N-methylcarboxamide (2-Cl-IB-MECA) during 15 min or two subsequent infusions of the vehicle during 15 min. 2-Cl-IB-MECA was dissolved in dimethylsulfoxide (DMSO) and diluted with a sodium chloride solution to a final 30% (v/v) DMSO solution (a total volume of 765 μl).?Fresh solutions were prepared prior to each experiment.The effect measurements were started at least 45 min prior to the first drug infusion and lasted until 4.5 h after this infusion.?Heart rate and blood pressure were recorded continuously and serial arterial blood samples were drawn for determination of plasma histamine concentrations.?2 h after the first administration the second dose of 2-Cl-IB-MECA (or vehicle) was administered[1]. |
| In vivo | The first infusion of Namodenoson resulted in a rapid fall of the blood pressure to a value which was about 50% of the pre-administration level.The hypotension was short-lasting.After approximately 15 min the blood pressure started to recover and rapidly returned to stable values, which were significantly lower than the blood pressure values in the control group.Administration of the second dose of Namodenoson, at 150 min after the first infusion, did not produce any hypotension at all.The slight increase in the mean arterial pressure during the second infusion was not specific for Namodenoson[1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 31 mg/mL (56.91 mM) |
| Keywords | CF 102 | inhibit | Inhibitor | Adenosine Receptor | P1 receptor | Namodenoson | CF102 |
| Inhibitors Related | Theophylline monohydrate | Diphylline | Acefylline | Nitrobenzylthioinosine | Aminophylline | Inosine | Theobromine | Istradefylline | Theophylline | Adenosine antagonist-1 | Doxofylline | FK-453 |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Neurotransmitter Receptor Compound Library | Drug Repurposing Compound Library | Anti-Viral Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1gram |
VIP4Y
|
Zhejiang J&C Biological Technology Co.,Limited
|
2022-02-17 | |
| $1.00/100g |
VIP5Y
|
Career Henan Chemical Co
|
2019-12-18 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY